Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant
Variants in the delta opioid receptor gene, OPRD1, were associated with opioid use disorder and response to treatment. The study goal was to assess whether OPRD1 variants predict survival and retention in methadone maintenance treatment (MMT). Retention and survival time since admission (June 1993 -...
Gespeichert in:
| Veröffentlicht in: | Drug and alcohol dependence 2023-09, Vol.250, p.110903-110903, Article 110903 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 110903 |
|---|---|
| container_issue | |
| container_start_page | 110903 |
| container_title | Drug and alcohol dependence |
| container_volume | 250 |
| creator | Peles, Einat Kim, Yuli Sason, Anat Adelson, Miriam Levran, Orna |
| description | Variants in the delta opioid receptor gene, OPRD1, were associated with opioid use disorder and response to treatment. The study goal was to assess whether OPRD1 variants predict survival and retention in methadone maintenance treatment (MMT).
Retention and survival time since admission (June 1993 - June 2022) until leaving treatment (for retention), or at the end of follow-up (Dec 2022) (for retention and survival) were analyzed in 488 patients. Vital data was taken from a national registry. Predictors were estimated using Kaplan-Meier and Cox regression models.
Longer retention and survival were found for carriers of the T allele of SNP rs204076. This SNP is associated with OPRD1 expression in cortex (GTEx). Carriers of the T allele (n = 251) survived longer compared to non-carriers (24.7 vs. 20.2 years, p = 0.005) and had longer retention (11.2 vs. 8.8 years, p = 0.04). Multivariate analysis identified the T allele as an independent predictor of longer survival time (p = 0.003) and retention (p = 0.009). Additional predictors for survival were no benzodiazepine use after one year in MMT, no hepatitis C, |
| doi_str_mv | 10.1016/j.drugalcdep.2023.110903 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11015812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0376871623011419</els_id><sourcerecordid>2845653978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-58de827c4bb3e83600b401256d7eff21c70318c9ef74617b054a4aac82d5dd7a3</originalsourceid><addsrcrecordid>eNqFkc-O1SAUxhujca6jr2BYuukVSgvUjRkn_ksm0YWuySmc3uGmhQq0yTyJrys3dxx1JQmcBd_5Dny_qiKM7hll4vVxb-N6gMlYXPYNbfieMdpT_qjaMSX7mtJWPK52lEtRK8nERfUspSMtS_T0aXXBZceZEGxX_fwa0TqTQ0wkjCRHhDyjzyRiLsUFT8Bbkta4uQ0mAnPwBzJjvgUbPNYzOJ_LRksWyK60pDfkiiwhJTdMSGIoxxgiATKu3pwMi4vFKQMJiwvOlkkGl_IAckCPZIPowOfn1ZMRpoQv7utl9f3D-2_Xn-qbLx8_X1_d1KZVNNedsqgaadph4Ki4oHRoKWs6YSWOY8OMpJwp0-MoW8HkQLsWWgCjGttZK4FfVm_Pvss6zGhN-UCESS_RzRDvdACn_73x7lYfwqZL4KxTrCkOr-4dYvixYsp6dsngNIHHsCbdqLYTHe-lKlJ1lppY8ok4PsxhVJ_A6qP-A1afwOoz2NL68u93PjT-JlkE784CLGltDqNOpuAwhW4JOGsb3P-n_ALtEr6Z</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2845653978</pqid></control><display><type>article</type><title>Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Peles, Einat ; Kim, Yuli ; Sason, Anat ; Adelson, Miriam ; Levran, Orna</creator><creatorcontrib>Peles, Einat ; Kim, Yuli ; Sason, Anat ; Adelson, Miriam ; Levran, Orna</creatorcontrib><description>Variants in the delta opioid receptor gene, OPRD1, were associated with opioid use disorder and response to treatment. The study goal was to assess whether OPRD1 variants predict survival and retention in methadone maintenance treatment (MMT).
Retention and survival time since admission (June 1993 - June 2022) until leaving treatment (for retention), or at the end of follow-up (Dec 2022) (for retention and survival) were analyzed in 488 patients. Vital data was taken from a national registry. Predictors were estimated using Kaplan-Meier and Cox regression models.
Longer retention and survival were found for carriers of the T allele of SNP rs204076. This SNP is associated with OPRD1 expression in cortex (GTEx). Carriers of the T allele (n = 251) survived longer compared to non-carriers (24.7 vs. 20.2 years, p = 0.005) and had longer retention (11.2 vs. 8.8 years, p = 0.04). Multivariate analysis identified the T allele as an independent predictor of longer survival time (p = 0.003) and retention (p = 0.009). Additional predictors for survival were no benzodiazepine use after one year in MMT, no hepatitis C, <20 years of opioid usage, and admission at age < 30. Additional predictors for longer retention were no use of other drugs except opioids on admission, and no drugs at one year, as well as methadone dose ≥ 100mg/d at one year and axis I & II DSM-5 psychiatric diagnosis.
The OPRD1 SNP rs204076 and non-genetic predictors contribute to survival time and retention in MMT patients.
•It is not known if and how genetic factors contribute to retention in methadone maintenance treatment (MMT).•The delta opioid receptor gene (OPRD1) variant rs204076 T allele may contribute to longer retention in MMT and survival.•Survival is also predicted by a shorter opioid usage, younger age at admission, no hepatitis C, and no benzodiazepine use.•Longer retention is also predicted by no drug use and methadone dose ≥ 100mg/day at one year in MMT.</description><identifier>ISSN: 0376-8716</identifier><identifier>ISSN: 1879-0046</identifier><identifier>EISSN: 1879-0046</identifier><identifier>DOI: 10.1016/j.drugalcdep.2023.110903</identifier><identifier>PMID: 37531661</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Analgesics, Opioid - therapeutic use ; Benzodiazepines - therapeutic use ; Delta opioid receptor gene ; Humans ; Methadone - therapeutic use ; Methadone maintenance treatment ; Opiate Substitution Treatment ; Opioid-Related Disorders - drug therapy ; Opioid-Related Disorders - genetics ; Opioid-Related Disorders - psychology ; OPRD1 ; Receptors, Opioid, delta - genetics ; Receptors, Opioid, delta - therapeutic use ; Retention ; rs204076 ; Survival</subject><ispartof>Drug and alcohol dependence, 2023-09, Vol.250, p.110903-110903, Article 110903</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-58de827c4bb3e83600b401256d7eff21c70318c9ef74617b054a4aac82d5dd7a3</citedby><cites>FETCH-LOGICAL-c480t-58de827c4bb3e83600b401256d7eff21c70318c9ef74617b054a4aac82d5dd7a3</cites><orcidid>0000-0002-5136-4184</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0376871623011419$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37531661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peles, Einat</creatorcontrib><creatorcontrib>Kim, Yuli</creatorcontrib><creatorcontrib>Sason, Anat</creatorcontrib><creatorcontrib>Adelson, Miriam</creatorcontrib><creatorcontrib>Levran, Orna</creatorcontrib><title>Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant</title><title>Drug and alcohol dependence</title><addtitle>Drug Alcohol Depend</addtitle><description>Variants in the delta opioid receptor gene, OPRD1, were associated with opioid use disorder and response to treatment. The study goal was to assess whether OPRD1 variants predict survival and retention in methadone maintenance treatment (MMT).
Retention and survival time since admission (June 1993 - June 2022) until leaving treatment (for retention), or at the end of follow-up (Dec 2022) (for retention and survival) were analyzed in 488 patients. Vital data was taken from a national registry. Predictors were estimated using Kaplan-Meier and Cox regression models.
Longer retention and survival were found for carriers of the T allele of SNP rs204076. This SNP is associated with OPRD1 expression in cortex (GTEx). Carriers of the T allele (n = 251) survived longer compared to non-carriers (24.7 vs. 20.2 years, p = 0.005) and had longer retention (11.2 vs. 8.8 years, p = 0.04). Multivariate analysis identified the T allele as an independent predictor of longer survival time (p = 0.003) and retention (p = 0.009). Additional predictors for survival were no benzodiazepine use after one year in MMT, no hepatitis C, <20 years of opioid usage, and admission at age < 30. Additional predictors for longer retention were no use of other drugs except opioids on admission, and no drugs at one year, as well as methadone dose ≥ 100mg/d at one year and axis I & II DSM-5 psychiatric diagnosis.
The OPRD1 SNP rs204076 and non-genetic predictors contribute to survival time and retention in MMT patients.
•It is not known if and how genetic factors contribute to retention in methadone maintenance treatment (MMT).•The delta opioid receptor gene (OPRD1) variant rs204076 T allele may contribute to longer retention in MMT and survival.•Survival is also predicted by a shorter opioid usage, younger age at admission, no hepatitis C, and no benzodiazepine use.•Longer retention is also predicted by no drug use and methadone dose ≥ 100mg/day at one year in MMT.</description><subject>Analgesics, Opioid - therapeutic use</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Delta opioid receptor gene</subject><subject>Humans</subject><subject>Methadone - therapeutic use</subject><subject>Methadone maintenance treatment</subject><subject>Opiate Substitution Treatment</subject><subject>Opioid-Related Disorders - drug therapy</subject><subject>Opioid-Related Disorders - genetics</subject><subject>Opioid-Related Disorders - psychology</subject><subject>OPRD1</subject><subject>Receptors, Opioid, delta - genetics</subject><subject>Receptors, Opioid, delta - therapeutic use</subject><subject>Retention</subject><subject>rs204076</subject><subject>Survival</subject><issn>0376-8716</issn><issn>1879-0046</issn><issn>1879-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-O1SAUxhujca6jr2BYuukVSgvUjRkn_ksm0YWuySmc3uGmhQq0yTyJrys3dxx1JQmcBd_5Dny_qiKM7hll4vVxb-N6gMlYXPYNbfieMdpT_qjaMSX7mtJWPK52lEtRK8nERfUspSMtS_T0aXXBZceZEGxX_fwa0TqTQ0wkjCRHhDyjzyRiLsUFT8Bbkta4uQ0mAnPwBzJjvgUbPNYzOJ_LRksWyK60pDfkiiwhJTdMSGIoxxgiATKu3pwMi4vFKQMJiwvOlkkGl_IAckCPZIPowOfn1ZMRpoQv7utl9f3D-2_Xn-qbLx8_X1_d1KZVNNedsqgaadph4Ki4oHRoKWs6YSWOY8OMpJwp0-MoW8HkQLsWWgCjGttZK4FfVm_Pvss6zGhN-UCESS_RzRDvdACn_73x7lYfwqZL4KxTrCkOr-4dYvixYsp6dsngNIHHsCbdqLYTHe-lKlJ1lppY8ok4PsxhVJ_A6qP-A1afwOoz2NL68u93PjT-JlkE784CLGltDqNOpuAwhW4JOGsb3P-n_ALtEr6Z</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Peles, Einat</creator><creator>Kim, Yuli</creator><creator>Sason, Anat</creator><creator>Adelson, Miriam</creator><creator>Levran, Orna</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5136-4184</orcidid></search><sort><creationdate>20230901</creationdate><title>Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant</title><author>Peles, Einat ; Kim, Yuli ; Sason, Anat ; Adelson, Miriam ; Levran, Orna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-58de827c4bb3e83600b401256d7eff21c70318c9ef74617b054a4aac82d5dd7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analgesics, Opioid - therapeutic use</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Delta opioid receptor gene</topic><topic>Humans</topic><topic>Methadone - therapeutic use</topic><topic>Methadone maintenance treatment</topic><topic>Opiate Substitution Treatment</topic><topic>Opioid-Related Disorders - drug therapy</topic><topic>Opioid-Related Disorders - genetics</topic><topic>Opioid-Related Disorders - psychology</topic><topic>OPRD1</topic><topic>Receptors, Opioid, delta - genetics</topic><topic>Receptors, Opioid, delta - therapeutic use</topic><topic>Retention</topic><topic>rs204076</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peles, Einat</creatorcontrib><creatorcontrib>Kim, Yuli</creatorcontrib><creatorcontrib>Sason, Anat</creatorcontrib><creatorcontrib>Adelson, Miriam</creatorcontrib><creatorcontrib>Levran, Orna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug and alcohol dependence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peles, Einat</au><au>Kim, Yuli</au><au>Sason, Anat</au><au>Adelson, Miriam</au><au>Levran, Orna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant</atitle><jtitle>Drug and alcohol dependence</jtitle><addtitle>Drug Alcohol Depend</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>250</volume><spage>110903</spage><epage>110903</epage><pages>110903-110903</pages><artnum>110903</artnum><issn>0376-8716</issn><issn>1879-0046</issn><eissn>1879-0046</eissn><abstract>Variants in the delta opioid receptor gene, OPRD1, were associated with opioid use disorder and response to treatment. The study goal was to assess whether OPRD1 variants predict survival and retention in methadone maintenance treatment (MMT).
Retention and survival time since admission (June 1993 - June 2022) until leaving treatment (for retention), or at the end of follow-up (Dec 2022) (for retention and survival) were analyzed in 488 patients. Vital data was taken from a national registry. Predictors were estimated using Kaplan-Meier and Cox regression models.
Longer retention and survival were found for carriers of the T allele of SNP rs204076. This SNP is associated with OPRD1 expression in cortex (GTEx). Carriers of the T allele (n = 251) survived longer compared to non-carriers (24.7 vs. 20.2 years, p = 0.005) and had longer retention (11.2 vs. 8.8 years, p = 0.04). Multivariate analysis identified the T allele as an independent predictor of longer survival time (p = 0.003) and retention (p = 0.009). Additional predictors for survival were no benzodiazepine use after one year in MMT, no hepatitis C, <20 years of opioid usage, and admission at age < 30. Additional predictors for longer retention were no use of other drugs except opioids on admission, and no drugs at one year, as well as methadone dose ≥ 100mg/d at one year and axis I & II DSM-5 psychiatric diagnosis.
The OPRD1 SNP rs204076 and non-genetic predictors contribute to survival time and retention in MMT patients.
•It is not known if and how genetic factors contribute to retention in methadone maintenance treatment (MMT).•The delta opioid receptor gene (OPRD1) variant rs204076 T allele may contribute to longer retention in MMT and survival.•Survival is also predicted by a shorter opioid usage, younger age at admission, no hepatitis C, and no benzodiazepine use.•Longer retention is also predicted by no drug use and methadone dose ≥ 100mg/day at one year in MMT.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>37531661</pmid><doi>10.1016/j.drugalcdep.2023.110903</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-5136-4184</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0376-8716 |
| ispartof | Drug and alcohol dependence, 2023-09, Vol.250, p.110903-110903, Article 110903 |
| issn | 0376-8716 1879-0046 1879-0046 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11015812 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Analgesics, Opioid - therapeutic use Benzodiazepines - therapeutic use Delta opioid receptor gene Humans Methadone - therapeutic use Methadone maintenance treatment Opiate Substitution Treatment Opioid-Related Disorders - drug therapy Opioid-Related Disorders - genetics Opioid-Related Disorders - psychology OPRD1 Receptors, Opioid, delta - genetics Receptors, Opioid, delta - therapeutic use Retention rs204076 Survival |
| title | Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T02%3A44%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20treatment%20retention%20and%20survival%20among%20methadone-maintained%20patients:%20A%20possible%20role%20for%20a%20functional%20delta%20opioid%20receptor%20gene%20variant&rft.jtitle=Drug%20and%20alcohol%20dependence&rft.au=Peles,%20Einat&rft.date=2023-09-01&rft.volume=250&rft.spage=110903&rft.epage=110903&rft.pages=110903-110903&rft.artnum=110903&rft.issn=0376-8716&rft.eissn=1879-0046&rft_id=info:doi/10.1016/j.drugalcdep.2023.110903&rft_dat=%3Cproquest_pubme%3E2845653978%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2845653978&rft_id=info:pmid/37531661&rft_els_id=S0376871623011419&rfr_iscdi=true |